Progyny, Inc. (NASDAQ:PGNY) Given Consensus Rating of “Moderate Buy” by Brokerages

Progyny, Inc. (NASDAQ:PGNY) has received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $25.4444.

Several equities research analysts recently weighed in on the company. Leerink Partners upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 target price for the company in a report on Tuesday, July 8th. JPMorgan Chase & Co. upped their price target on Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target (up from $26.00) on shares of Progyny in a report on Friday, August 8th. Canaccord Genuity Group upped their price target on Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 20th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a research report on Wednesday.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 2,398 shares of the company’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the sale, the executive vice president directly owned 79,697 shares in the company, valued at $1,829,843.12. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kevin K. Gordon sold 2,500 shares of the company’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the sale, the director owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,895 shares of company stock worth $179,311. 9.40% of the stock is currently owned by company insiders.

Institutional Trading of Progyny

Large investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Progyny in the first quarter valued at $354,000. GAMMA Investing LLC increased its position in Progyny by 233.9% in the first quarter. GAMMA Investing LLC now owns 5,379 shares of the company’s stock worth $120,000 after purchasing an additional 3,768 shares during the period. Oppenheimer Asset Management Inc. lifted its position in Progyny by 18.7% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 34,675 shares of the company’s stock valued at $775,000 after purchasing an additional 5,459 shares during the period. Voya Investment Management LLC lifted its position in Progyny by 258.2% during the 1st quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock valued at $4,144,000 after purchasing an additional 133,703 shares during the period. Finally, Millennium Management LLC lifted its position in Progyny by 7.5% during the 1st quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock valued at $29,107,000 after purchasing an additional 90,367 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Progyny Stock Performance

PGNY opened at $20.10 on Monday. The business has a 50 day moving average price of $22.30 and a 200 day moving average price of $22.21. Progyny has a twelve month low of $13.39 and a twelve month high of $26.76. The firm has a market cap of $1.73 billion, a P/E ratio of 34.07, a price-to-earnings-growth ratio of 1.75 and a beta of 1.34.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The company had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. During the same quarter last year, the firm posted $0.17 earnings per share. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.